CoChat

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24‐week randomized placebo‐controlled trial

Lukashevich, V., Schweizer, A., Shao, Q., Groop, P.‐H., Kothny, W. · 2011 · Diabetes, Obesity and Metabolism
Cited by 146

The DOI matches its Crossref record.

Abstract

Aim: Assess safety/tolerability and efficacy of the DPP‐4 inhibitor vildagliptin in 515 patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal impairment (RI). Methods: Double‐blind, randomized, parallel‐group, placebo‐controlled, 24‐week clinical trial assessing safety and efficacy of vildagliptin (50 mg qd) added to current antidiabetic therapy, in patients with T2DM and moderate or severe RI (GFR ≥ 30 to <50 or <30 ml/min/1.73 m 2 ). Results: The study population comprised of 165 and 129 patients with moderate RI and 124 and 97 patients with severe RI randomized to vildagliptin and placebo, respectively, with most patients receiving background insulin therapy (68 and 81% for moderate and severe RI, respectively). After 24 weeks, the between‐treatment difference in the adjusted mean change in A1C was −0.5 ± 0.1% (p < 0.0001) in moderate RI (baseline A1C = 7.9%) and −0.6 ± 0.1% (p < 0.0001) in severe RI (baseline A1C = 7.7%). In patients with moderate RI, similar proportions of those receiving vildagliptin or placebo experienced any AE (68 vs. 73%), any SAE (9 vs. 9%), any AE leading to discontinuation (3 vs. 5%) or death (1 vs. 1%). This was also true for patients with severe RI: AEs (73 vs. 74%), SAEs (19 vs. 21%), AEs leading to discontinuation (9 vs. 6%) and death (2 vs. 4%). Conclusions: In this 24‐week study of 515 patients with T2DM and moderate or severe RI, vildagliptin added to ongoing antidiabetic therapy had a safety profile similar to placebo. Further, relative to placebo, vildagliptin elicited a statistically and clinically significant decrease in A1C in patients with moderate or severe RI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01467.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 20

  1. 10.5694/j.1326-5377.2006.tb00499.x · DOI · Paper page
  2. 10.1053/j.ajkd.2007.08.012 · DOI
  3. 10.1592/phco.30.5.463 · DOI · Paper page
  4. 10.1111/j.1463-1326.2010.01215.x · DOI · Paper page
  5. 10.2147/VHRM.S16925 · DOI
  6. 10.1111/j.1463-1326.2010.01214.x · DOI · Paper page
  7. 10.1186/1472-6823-8-14 · DOI · Paper page
  8. 10.1111/j.1463-1326.2011.01382.x · DOI · Paper page
  9. 10.1111/j.1463-1326.2008.00914.x · DOI · Paper page
  10. 10.1124/dmd.108.023010 · DOI
  11. 10.1016/j.diabres.2006.12.009 · DOI · Paper page
  12. 10.1055/s-2007-970422 · DOI · Paper page
  13. 10.1111/j.1463-1326.2010.01325.x · DOI · Paper page
  14. 10.1016/j.diabres.2010.06.022 · DOI
  15. 10.1111/j.1463-1326.2011.01414.x · DOI · Paper page
  16. 10.1007/s00125-007-0633-0 · DOI · Paper page
  17. 10.1111/j.1463-1326.2008.00859.x · DOI · Paper page
  18. 10.2337/dc07-1188 · DOI
  19. 10.1007/s11892-009-0076-8 · DOI
  20. 10.1210/jc.2008-2152 · DOI · Paper page

Cited by

See all 146

Metadata

Authors
Lukashevich, V., Schweizer, A., Shao, Q., Groop, P. ‐., & Kothny, W.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-09-06
Volume
13
Issue
10
Pages
947-954
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2079841945
Cited by
146
References
0
FWCI
18.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24‐week randomized placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01467.x
The paper
Lukashevich, V., Schweizer, A., Shao, Q., Groop, P. ‐., & Kothny, W. (2011). Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24‐week randomized placebo‐controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01467.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.